Evidence map›Paper›PMID 39199470›Full record

ReviewBrain sciences2024

Non-Ergot Dopamine Agonists and the Risk of Heart Failure and Other Adverse Cardiovascular Reactions in Parkinson's Disease.

James A G Crispo, Nawal Farhat, Yannick Fortin, Santiago Perez-Lloret, Lindsey Sikora, Rebecca L Morgan, Mara Habash, Priyanka Gogna, Shannon E Kelly, Jesse Elliott and 6 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Brain sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. How to treat cardiovascular autonomic failure in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

James A G CrispoMcLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.
Nawal FarhatMcLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.
Yannick FortinMcLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.
Santiago Perez-LloretObservatorio de Salud, Pontificia Universidad Católica Argentina, Consejo de Investigaciones Científicas y Técnicas (UCA-CONICET), Buenos Aires C1107AAZ, Argentina.ORCID 0000-0001-9069-6512
Lindsey SikoraHealth Sciences Library, University of Ottawa, Ottawa, ON K1H 8M5, Canada.ORCID 0000-0002-9715-8634
Rebecca L MorganDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON L8S 4L8, Canada.
Mara HabashAboriginal Cancer Control Unit, Cancer Care Ontario, Toronto, ON M5G 2L7, Canada.
Priyanka GognaDepartment of Public Health Sciences, Queen's University, Kingston, ON K7L 3N6, Canada.
Shannon E KellySchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.
Jesse ElliottSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.
Dafna E KohenSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.
Lise M BjerreSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.
Donald R MattisonMcLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.
Renée C HessianUniversity of Ottawa Heart Institute, University of Ottawa, Ottawa, ON K1Y 4W7, Canada.
Allison W WillisDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Daniel KrewskiMcLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.

Funding

Midcareer Development Award in Neuroaging and Geriatric Pharmacoepidemiology ResearchK24AG075234 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Allison Willis · 2022 to 2026
$808k
McLaughlin Centre for Population Health Risk Assessment at the University of Ottawa n/aNIA NIH HHS K24 AG075234
6 · The paper itself

Abstract

Reports suggest possible risks of adverse cardiovascular reactions, including heart failure, associated with non-ergot dopamine agonist (DA) use in Parkinson's disease (PD). The objectives of our review were to evaluate the risk of heart failure and other adverse cardiovascular reactions in PD patients who received a non-ergot DA compared with other anti-PD pharmacological interventions, placebo, or no intervention. Studies were identified via searches of six bibliographic databases. Randomized controlled trials (RCTs) and non-randomized studies (NRS) were eligible for study inclusion. Random-effect meta-analyses were performed to estimate adverse cardiovascular reaction risks. Quality of evidence was assessed using GRADE. In total, forty-four studies (thirty-six RCTs and eight NRS) satisfied our inclusion criteria. A single RCT found no significant difference in the risk of heart failure with ropinirole compared with bromocriptine (odds ratio (OR) 0.39, 95% confidence interval (CI) 0.07 to 2.04; low certainty). Conversely, three case-control studies reported a risk of heart failure with non-ergot DA treatment. The quality of evidence for the risk of heart failure was judged as low or very low. Findings suggest that non-ergot DA use may be associated with adverse cardiovascular outcomes, including heart failure. Studies are needed to better understand cardiovascular risks associated with PD treatment.

Indexed as

cardiovascular reactionsheart failuremedication safetymeta-analysisnon-ergot dopamine agonistsnon-randomized studiesParkinson’s diseaserandomized controlled trialssystematic review

Identifiers

PMID39199470
PMCPMC11352331

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.